

نتایج مطالعه بار بیماری ایران به تفکیک استان - ۱۹۹۰ تا ۲۰۱۹

اردشیر خسروی

عضو هیات علمی و معاون فنی مرکز مدیریت شبکه

مقدمه

- مطالعه بار بیماری ها از سال ۱۹۹۰ توسط دانشگاه هاروارد و با همکاری سازمان جهانی بهداشت شروع و هر چند سال یک با این مطالعه انجام می شود.
- آخرین مطالعه بر آورد ها بار بیماری ها برای سال ۲۰۱۹ بوده است. در این مطالعه، بار بیماری ها برای ۳۶۹ بیماری و صدمات و ۸۷ عامل خطر برای ۲۰۴ کشور از سال ۱۹۹۰ تا ۲۰۱۹ انجام شد ضمنا برای ۲۱ کشور از جمله ایران به تفکیک استانی انجام شد

شاخص های مهم بار بیماری ها

- مهمترین شاخص بار بیماری ها به شرح زیر است:

- بار کلی بیماری با استفاده از **سال های زندگی تعدیل شده با ناتوانی (DALY)** ارزیابی می شود، که معیاری مبتنی بر زمان است که ترکیبی از:

- سال های زندگی از دست رفته به دلیل مرگ و میر زودرس (YLLs)

- و سال های زندگی از دست رفته به دلیل زمان زندگی در وضعیت کمتر از سلامت کامل، یا سالهای زندگی سالم از دست رفته به دلیل ناتوانی (YLDs).

- یک DALY نشان دهنده از دست دادن معادل یک سال سلامت کامل است. با استفاده از DALY، بار بیماری هایی که باعث مرگ زودرس می شوند اما ناتوانی اندک (مانند غرق شدن) را می توان با بیماری هایی که باعث مرگ نمی شوند اما باعث ناتوانی می شوند (مانند آب مروارید که باعث نابینایی می شود) مقایسه کرد.

Health system performance in Iran: a systematic analysis for the Global Burden of Disease Study 2019

GBD 2019 Iran Collaborators*

Summary

Background Better evaluation of existing health programmes, appropriate policy making against emerging health threats, and reducing inequalities in Iran rely on a comprehensive national and subnational breakdown of the burden of diseases, injuries, and risk factors.

Methods In this systematic analysis, we present the national and subnational estimates of the burden of disease in Iran using the Global Burden of Disease Study 2019. We report trends in demographics, all-cause and cause-specific mortality, as well as years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) caused by major diseases and risk factors. A multi-intervention segmented-regression model was used to explore the overall impact of health sector changes and sanctions. For this analysis, we used a variety of sources and reports, including vital registration, census, and survey data to provide estimates of mortality and morbidity at the national and subnational level in Iran.

Findings Iran, which had 84·3 million inhabitants in 2019, had a life expectancy of 79·6 years (95% uncertainty interval 79·2–79·9) in female individuals and 76·1 (75·6–76·5) in male individuals, an increase compared with 1990. The number of DALYs remained stable and reached 19·8 million (17·3–22·6) in 2019, of which 78·1% were caused by non-communicable diseases (NCDs) compared with 43·0% in 1990. During the study period, age-standardised DALY rates and YLL rates decreased considerably; however, YLDs remained nearly constant. The share of age-standardised YLDs contributing to the DALY rate steadily increased to 44·5% by 2019. With regard to the DALY rates of different provinces, inequalities were decreasing. From 1990 to 2019, although the number of DALYs attributed to all risk factors decreased by 16·8%, deaths attributable to all risk factors substantially grew by 43·8%. The regression results revealed a significant negative association between sanctions and health status.

Interpretation The Iranian health-care system is encountering NCDs as its new challenge, which necessitates a coordinated multisectoral approach. Although the Iranian health-care system has been successful to some extent in controlling mortality, it has overlooked the burden of morbidity and need for rehabilitation. We did not capture alleviation of the burden of diseases in Iran following the 2004 and 2014 health sector reforms; however, the sanctions were associated with deaths of Iranians caused by NCDs.

Funding Bill & Melinda Gates Foundation.

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction

During the past four decades, Iran has experienced substantial turmoil in its economy and international policy. After the 1979 revolution, Iran was afflicted with the longest war in the 20th century with its neighbour Iraq.¹ After the end of the war in 1988, Iran entered an era of massive construction and investment in its health and

UHC, Iran has undergone several major transformations, including expanding the primary health-care (PHC) system² and integrating the Ministry of Health with Medical Education in the 1980s,³ the 2004 Universal Rural Health Insurance,^{1,6,7} and the 2014 Health Transformation Plan;⁸ however, existing evidence indicates unequal improvements in the distribution of specific health



Lancet 2022; 399: 1625–45

Published Online
April 6, 2022
[https://doi.org/10.1016/S0140-6736\(21\)02751-3](https://doi.org/10.1016/S0140-6736(21)02751-3)

See [Comment](#) page 1577

*Collaborators listed at the end of the paper

Correspondence to:
Prof Mohsen Naghavi,
Department of Health Metrics
Sciences, Institute for Health
Metrics and Evaluation, School
of Medicine, University
of Washington, Seattle,
WA 98195, USA
naghham@uw.edu

خلاصه نتایج کلی بار بیماری های ایران ۱


در سال ۱۹۹۰ اختلاف بالاترین امید زندگی

استانی با پایین ترین امید زندگی استانی **۱۲/۵**


سال بوده است ولی در سال ۲۰۱۹ به **۸/۲** سال

کاهش یافته است.

امید زندگی سال ۱۹۹۰ میلادی



امید زندگی سال ۲۰۱۹ میلادی



خلاصه نتایج کلی بار بیماری های ایران ۲

در سال ۱۹۹۰ اختلاف بالاترین امید زندگی
استانی با پایین ترین امید زندگی استانی $۱۲/۵$
سال بوده است ولی در سال ۲۰۱۹ به $۸/۲$ سال
کاهش یافته است.

امید زندگی به تفکیک استان زن و مرد سال ۲۰۱۹










Figure 1: Life expectancy at birth (years) among provinces of Iran in male and female individuals, 2019


خلاصه نتایج کلی بار بیماری های ایران ۲


• کاهش علی که باعث بیشترین نقش را در افزایش امید زندگی کشوری داشته است

بیماری های قلبی عروقی	←	۲/۹ سال
حوادث غیر عمد	←	۲/۶ سال
نوزادان و مادران	←	۱/۸ سال
حوادث ترافیکی	←	۰/۹ سال

تعدادی از بیماری ها نیز تاثیر خیلی کمی در کاهش داشته اند شامل: دیابت، بیماری های کلیوی، ایدز و HIV و بیماری ها منتقل شده از راه جنسی، مصرف مواد، بیماری ها اسکلتی عضلانی







خلاصه نتایج کلی بار بیماری های ایران ۴

• در سال ۲۰۱۹، کل میزان DALYS به ۱۹/۸ میلیون سال رسید است

• از این تعداد ۷۸/۱ درصد NCD در سال ۲۰۱۹ بوده در صورتی که در سال ۱۹۹۰ این میزان ۴۳ درصد بوده است.


• شاخص سطح دگرگونی اپیدمیولوژیک که به صورت :

• نسبت DALYs علل بیماری های واگیر مادران و نوزان به میزان DALYS علل غیر واگیر و حوادث است که در دامنه آن در استان ها عبارت است:

• ۸/۰ درصد و ۱۰۳/۲ درصد در سال ۱۹۹۰ و از ۵/۱ درصد تا ۲۳ درصد در سال ۲۰۱۹

Appendix figure 6


1990



Epidemiological transition level (%)

- < 42.9
- [42.9 to 50.4)
- [50.4 to 56.3)
- [56.3 to 64.6)
- ≥ 64.6


2019




Epidemiological transition level (%)

- < 8.3
- [8.3 to 8.8)
- [8.8 to 10.3)
- [10.3 to 11.3)
- ≥ 11.3


میزان استاندارد شده DALYs در ۱۰۰ هزار نفر به تفکیک استان در سال ۲۰۱۹




میزان استاندارد شده YLLs در ۱۰۰ هزار نفر به تفکیک استان در سال ۲۰۱۹



میزان استاندارد شده YLDs در ۱۰۰ هزار نفر به تفکیک استان در سال ۲۰۱۹



Both sexes, All ages, 2019



Switch cause group


Add cause

- HIV/AIDS & STIs
- Respiratory infections & TB
- Enteric infections
- NTDs & malaria
- Other infectious
- Maternal & neonatal
- Nutritional deficiencies
- Neoplasms
- Cardiovascular diseases
- Chronic respiratory
- Digestive diseases
- Neurological disorders
- Mental disorders
- Substance use
- Diabetes & CKD
- Skin diseases
- Sense organ diseases
- Musculoskeletal disorders
- Other non-communicable
- Transport injuries
- Unintentional inj
- Self-harm & violence

Clear selection



Both sexes, Age-standardized, 2019



میزان DALYs استاندارد شده منی در 100 هزار نفر سال 2019

استان	Cardiovascular diseases	Chronic respiratory diseases	Diabetes and kidney diseases	Digestive diseases	Enteric infections	HIV/AIDS and sexually transmitted infections	Maternal and neonatal disorders	Mental disorders	Musculoskeletal disorders	Neglected tropical diseases and malaria	Neoplasms	استان
البرز	5,151	691	1,453	505	258	51	892	2,347	1,980	15	2,181	البرز
اردبیل	6,394	720	1,459	467	268	41	1,334	2,339	1,949	22	3,151	اردبیل
بوشهر	5,982	655	1,501	560	270	78	1,332	2,331	1,932	17	2,211	بوشهر
چهارمحال و بختیاری	5,417	592	881	376	267	25	900	2,108	1,898	15	1,935	چهارمحال و بختیاری
آذربایجان شرقی	6,044	1,114	1,610	602	271	34	1,001	2,095	1,808	19	3,012	آذربایجان شرقی
فارس	5,821	745	1,314	630	265	135	1,315	2,547	1,922	20	2,208	فارس
گیلان	6,128	734	1,430	458	257	30	723	2,149	1,905	14	2,437	گیلان
گلستان	7,577	974	1,639	738	279	39	1,361	2,094	1,960	19	2,715	گلستان
همدان	6,211	830	1,184	635	284	40	1,516	2,104	1,933	18	2,368	همدان
هرمزگان	5,916	586	1,422	625	317	240	1,363	2,340	1,951	21	1,650	هرمزگان
ایلام	5,992	603	1,549	481	273	25	1,372	2,417	1,961	17	2,684	ایلام
کل کشور	5,077	794	1,506	550	274	89	1,258	2,296	2,007	18	2,321	کل کشور
اصفهان	4,822	783	1,479	508	260	31	1,189	2,245	1,952	17	2,189	اصفهان
کرمان	5,406	1,371	1,341	599	312	108	1,650	2,427	1,847	22	2,179	کرمان
کرمانشاه	6,172	843	1,304	606	277	320	1,540	2,330	1,965	18	2,484	کرمانشاه
خراسان رضوی	5,643	1,099	1,624	644	294	41	1,353	2,119	1,945	20	2,721	خراسان رضوی
خوزستان	6,507	674	2,019	545	275	80	1,277	2,338	1,904	20	2,128	خوزستان
کهگیلویه و بویر احمد	5,537	558	1,018	457	273	54	1,113	2,344	1,913	20	2,173	کهگیلویه و بویر احمد
کردستان	5,339	744	1,225	546	274	41	1,651	2,180	1,933	18	2,691	کردستان
لرستان	6,389	640	1,153	513	262	187	878	2,097	1,935	16	2,460	لرستان
مرکزی	4,708	783	1,347	532	263	33	1,298	2,345	1,922	16	2,285	مرکزی
مازندران	5,186	631	1,693	445	246	26	895	2,305	2,506	15	2,379	مازندران
خراسان شمالی	6,112	932	1,520	632	308	41	1,366	2,344	1,961	25	2,663	خراسان شمالی
قزوین	5,184	774	1,215	793	259	31	1,117	2,124	1,928	15	2,404	قزوین
قم	4,398	808	1,408	578	262	166	906	2,343	1,877	17	2,429	قم
سمنان	5,165	830	1,639	537	251	22	1,163	2,164	1,915	15	2,368	سمنان
سیستان و بلوچستان	6,110	1,300	1,825	892	370	152	1,998	2,350	1,902	42	2,210	سیستان و بلوچستان
خراسان جنوب	4,401	1,102	1,520	629	295	28	1,487	2,347	1,950	20	2,311	خراسان جنوب
تهران	2,604	553	1,598	441	233	146	948	2,391	2,248	13	1,861	تهران
آذربایجان غربی	6,267	952	1,374	562	294	37	1,335	2,409	1,939	17	3,060	آذربایجان غربی
یزد	4,727	892	1,787	486	268	45	1,359	2,130	1,922	15	2,361	یزد
زنجان	5,109	835	961	520	268	41	1,555	2,342	1,904	18	2,127	زنجان

میزان DALYs استاندارد شده سنی در 100 هزار نفر سال 2019

استان	Neurological disorders	Nutritional deficiencies	Other infectious diseases	Other non-communicable diseases	Respiratory infections and tuberculosis	Self-harm and interpersonal violence	Sense organ diseases	Skin and subcutaneous diseases	Substance use disorders	Transport injuries	Unintentional injuries	استان	Grand Total
البرز	1,386	129	108	1,808	597	627	783	425	478	934	966	البرز	23,766
اردبیل	1,410	153	126	2,247	321	615	815	421	310	1,112	899	اردبیل	26,570
بوشهر	1,354	171	113	2,065	461	527	800	425	284	1,462	817	بوشهر	25,351
چهارمحال و بختیاری	1,338	146	91	1,863	265	479	841	420	290	1,348	821	چهارمحال و بختیاری	22,318
آذربایجان شرقی	1,472	159	118	2,077	514	529	814	425	383	1,578	945	آذربایجان شرقی	26,623
فارس	1,452	148	126	2,178	541	847	799	420	464	2,240	1,068	فارس	27,203
گیلان	1,384	141	92	1,734	349	501	759	422	327	1,430	1,187	گیلان	24,591
گلستان	1,432	170	192	2,191	550	673	812	426	281	1,908	1,071	گلستان	29,101
همدان	1,414	160	171	2,091	495	816	815	421	604	1,888	1,043	همدان	27,041
هرمزگان	1,380	172	140	2,064	540	575	819	420	478	1,906	971	هرمزگان	25,895
ایلام	1,379	153	123	2,120	378	1,049	805	421	232	1,566	977	ایلام	26,576
کل کشور	1,394	157	132	2,054	507	565	811	423	400	1,383	1,013	کل کشور	25,029
اصفهان	1,420	164	113	2,102	455	419	796	423	332	1,246	983	اصفهان	23,928
کرمان	1,396	168	153	2,097	673	653	809	419	346	1,980	1,486	کرمان	27,439
کومانشاه	1,382	170	139	2,110	536	921	817	421	510	1,807	1,095	کومانشاه	27,765
خراسان رضوی	1,402	159	137	2,145	715	527	1,036	422	414	1,663	997	خراسان رضوی	27,119
خوزستان	1,370	171	149	2,232	643	764	776	425	383	1,443	1,171	خوزستان	27,293
کهگیلویه و بویر احمد	1,379	154	162	2,010	370	874	809	421	274	1,737	1,194	کهگیلویه و بویر احمد	24,843
کردستان	1,403	162	120	2,012	390	628	791	422	265	1,729	924	کردستان	25,488
لرستان	1,350	177	145	1,731	422	742	809	419	492	1,448	810	لرستان	25,076
مرکزی	1,391	157	121	1,941	525	534	809	422	369	1,531	927	مرکزی	24,259
مازندران	1,371	136	94	1,892	376	523	784	422	234	1,509	972	مازندران	24,641
خراسان شمالی	1,418	175	167	2,111	744	557	818	424	339	1,745	1,049	خراسان شمالی	27,451
قزوین	1,400	151	107	1,930	403	447	812	424	469	1,343	914	قزوین	24,245
قم	1,366	154	109	1,881	503	601	807	431	291	719	1,010	قم	23,066
سمنان	1,403	145	90	1,961	580	480	753	424	334	1,342	819	سمنان	24,398
سیستان و بلوچستان	1,432	226	339	2,264	788	734	857	420	514	2,346	1,272	سیستان و بلوچستان	30,342
خراسان جنوب	1,383	176	137	2,040	721	384	814	421	364	1,597	911	خراسان جنوب	25,039
تهران	1,362	130	97	1,931	375	273	757	428	520	330	904	تهران	20,145
آذربایجان غربی	1,433	167	139	2,182	497	771	829	422	222	1,507	923	آذربایجان غربی	27,337
یزد	1,397	144	99	2,144	579	515	761	427	318	1,304	897	یزد	24,573
زنجان	1,356	153	115	1,913	460	408	814	420	329	1,240	1,087	زنجان	23,978

Both sexes, Age-standardized, 2019, DALYs per 100,000

Higher rank  Lower rank

	Alborz	Ardebil	Bushehr	Chaharmahal and Chalus	E Azarbaijan	Fars	Gilan	Golestan	Hamadan	Hormozgan	Ilam	Isfahan	Kerman	Kermanshah	Khorasan	Khuzestan	Kohgiluyeh and Boyer-Ahmad	Kurdistan	Lorestan	Markazi	Mazandaran	N Khorasan	Qazvin	Qom	Semnan	Sistan and Baluchistan	S Khorasan	Tehran	W Azarbaijan	Yazd	Zanjan	Iran (Islamic Republic of)			
Ischemic heart disease	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1		
Road injuries	6	4	3	2	2	2	3	2	2	2	2	2	2	2	2	4	2	2	3	2	3	2	3	9	3	2	2	22	3	5	4	2			
Stroke	2	2	2	3	3	3	2	3	4	3	4	4	4	3	3	2	3	4	2	4	4	3	2	2	2	2	4	4	6	2	3	3	3		
Neonatal disorders	7	3	4	5	5	4	7	4	3	4	3	3	3	4	4	5	4	3	5	3	7	4	4	4	4	4	3	3	5	4	2	2	4		
Diabetes	3	8	5	10	6	8	4	5	10	7	9	5	9	8	5	3	10	8	8	7	5	6	7	6	5	10	5	2	8	4	11	5			
Low back pain	5	7	7	4	8	6	5	6	5	6	6	6	7	6	6	7	6	5	4	6	2	7	5	5	6	7	7	7	3	6	6	6	6		
Depressive disorders	4	6	6	6	11	5	6	10	7	5	5	7	6	5	9	6	5	6	9	5	6	5	6	3	7	6	6	4	5	8	5	7			
Congenital defects	10	5	8	9	7	7	12	7	6	9	7	8	8	7	7	8	9	7	13	11	11	9	10	10	10	10	8	8	9	7	7	9	8		
Headache disorders	8	10	9	7	10	9	8	8	8	8	10	9	10	9	10	9	7	9	6	8	8	10	8	7	8	12	9	7	9	10	7	9			
Anxiety disorders	9	11	10	8	12	10	9	9	9	10	11	10	11	10	11	10	8	10	7	9	9	11	9	8	9	13	10	8	10	9	8	10			
COPD	12	16	15	19	9	13	14	13	12	22	20	11	5	11	8	15	23	15	18	14	19	13	12	11	13	9	11	18	13	11	10	11			
Gynecological diseases	11	14	11	11	15	12	11	14	13	13	15	12	16	14	16	11	11	13	11	13	12	15	11	13	14	14	13	10	14	13	12	12			
Hypertensive heart disease	22	13	12	12	4	11	10	11	16	11	13	17	15	15	12	14	17	11	10	10	10	8	16	26	11	11	15	39	12	12	13	13			
Chronic kidney disease	16	12	13	23	13	14	13	12	14	12	8	13	12	13	15	12	13	14	15	12	13	14	13	12	12	5	14	17	15	14	18	14			
Neck pain	17	17	16	14	17	17	16	17	17	16	17	15	17	18	19	16	15	16	17	15	16	18	17	15	16	19	17	11	17	16	15	15			
Other musculoskeletal	14	19	14	18	16	18	19	16	20	15	16	14	23	17	18	19	19	19	21	18	15	17	20	19	18	24	16	13	20	18	20	16			
Age-related hearing loss	19	18	17	13	18	20	17	20	18	17	19	18	19	19	21	17	16	17	19	16	18	19	19	16	17	18	19	14	18	19	16	17			
Alzheimer's disease	18	20	18	17	19	19	18	22	19	19	18	16	18	21	20	18	18	18	20	17	17	20	18	17	19	20	18	16	19	17	17	18			
Blindness and vision loss	20	22	20	16	22	21	20	23	22	20	21	19	21	22	13	22	22	21	22	20	20	21	22	18	22	21	21	19	21	21	19	19			
Lower respiratory infect	13	36	21	34	21	16	32	25	24	18	29	21	14	20	14	13	29	26	26	19	25	12	27	20	15	15	12	24	22	15	21	20			
Drug use disorders	15	28	27	25	23	15	25	34	11	14	33	23	26	16	22	21	30	30	14	22	31	27	15	27	24	16	24	12	38	25	25	21			
Endo/metab/blood/immune	24	23	22	22	24	23	22	21	25	21	23	20	22	25	24	20	21	23	24	24	21	22	25	22	21	23	22	15	24	20	24	22			
Stomach cancer	26	9	34	15	14	31	15	15	23	37	14	28	32	27	17	31	12	12	12	21	14	16	21	23	20	30	23	32	11	36	14	23			
Oral disorders	25	24	23	21	27	27	23	28	26	23	24	22	24	26	27	23	24	24	23	25	22	25	24	21	23	28	26	21	25	22	23	24			
Falls	21	26	24	20	28	22	29	29	21	26	26	24	30	23	25	30	20	22	27	23	23	23	23	28	26	32	27	23	27	24	22	25			



Both sexes, Age-standardized, 2019, YLLs per 100,000



Higher rank Lower rank

	Alborz	Ardebil	Bushehr	Chaharmahal and Kohgiluyeh	E Azarbaijan	Fars	Gilan	Golestan	Hamadan	Hormozgan	Ilam	Isfahan	Kerman	Kermanshah	Khorasan	Khuzestan	Kohgiluyeh	Kurdistan	Lorestan	Markazi	Mazandaran	N Khorasan	Qazvin	Qom	Semnan	Sistan and Baluchistan	S Khorasan	Tehran	W Azarbaijan	Yazd	Zanjan	Iran (Islamic Republic of)	
Ischemic heart disease	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
Road injuries	3	4	3	2	2	2	3	2	2	2	2	2	2	2	2	3	2	2	3	2	2	2	3	4	2	2	2	8	2	2	4	2	
Stroke	2	2	2	3	3	3	2	3	4	3	4	3	4	3	3	2	3	4	2	4	3	3	2	2	3	4	4	4	4	3	3	3	3
Neonatal disorders	4	3	4	4	5	4	5	4	3	4	3	4	3	4	4	4	4	4	3	5	3	4	4	4	3	4	3	3	2	4	4	2	4
Congenital defects	5	5	5	5	6	5	8	5	5	6	5	5	6	5	5	6	5	5	8	6	7	6	5	5	5	5	6	5	5	5	5	5	5
Hypertensive heart disease	9	7	7	6	4	6	4	6	7	5	8	7	8	7	6	8	8	7	4	5	5	5	7	15	6	7	8	22	7	7	7	6	
Diabetes	7	11	6	14	12	9	7	7	17	10	13	6	14	16	12	5	18	14	15	11	6	16	14	10	7	11	18	3	13	6	17	7	
Chronic kidney disease	11	8	9	13	8	8	9	8	9	7	6	9	9	8	10	9	9	8	9	7	9	9	9	6	9	5	9	7	10	10	12	8	
Lower respiratory infect	6	19	10	15	11	7	15	12	11	8	14	10	7	10	7	7	12	13	11	8	12	7	13	8	8	9	6	9	11	9	9	9	
Stomach cancer	13	6	15	7	7	17	6	9	8	18	9	13	15	12	9	15	6	6	6	9	8	8	8	11	11	12	10	16	6	17	6	10	
COPD	10	14	12	12	9	11	11	11	10	16	16	8	5	9	8	11	15	10	13	10	13	10	10	7	10	8	7	17	9	8	8	11	
Lung cancer	14	9	8	9	10	13	10	14	12	14	10	12	10	11	11	10	11	9	10	13	11	12	12	13	12	18	12	13	8	11	11	12	
Alzheimer's disease	12	13	11	8	14	14	12	16	15	11	12	11	12	15	14	12	10	11	12	12	10	13	11	12	13	14	11	6	14	12	10	13	
Self-harm	8	12	16	10	15	10	14	15	6	12	7	19	16	6	18	13	7	12	7	18	17	14	20	20	18	20	19	20	12	19	21	14	
Cirrhosis	17	20	13	21	16	12	19	10	14	9	21	15	11	14	13	14	19	15	14	14	18	11	6	14	15	10	13	18	16	18	13	15	
Leukemia	22	17	14	11	18	18	16	20	16	17	19	14	17	19	15	18	13	18	18	15	15	19	18	17	17	23	16	15	17	14	16	16	
Colorectal cancer	15	16	18	16	13	23	13	19	20	20	18	16	21	21	17	20	22	16	17	16	14	18	15	16	14	24	17	14	18	13	14	17	
Breast cancer	18	21	17	22	19	21	18	22	22	19	22	18	22	23	21	17	24	20	23	19	16	24	19	18	16	25	20	12	22	16	19	18	
Other cardiovascular	26	10	21	17	17	19	17	13	18	13	15	20	13	18	16	21	23	17	27	23	24	15	22	30	22	13	15	35	15	20	15	19	
Brain cancer	21	22	20	20	20	22	22	25	23	25	23	21	19	22	22	23	20	23	22	17	20	25	17	19	19	35	22	19	21	15	20	20	
Drug use disorders	16	29	28	23	24	20	24	32	13	22	40	25	26	20	20	24	31	31	16	22	37	27	16	31	24	22	23	11	40	26	23	21	
Mechanical forces	29	30	34	31	29	31	27	21	25	24	25	17	20	32	28	19	17	26	29	24	31	26	33	9	29	19	28	10	25	23	30	22	
Interpersonal violence	19	23	19	26	30	16	29	23	24	21	11	27	18	17	26	16	14	24	31	27	23	21	28	24	28	15	32	39	19	34	28	23	
Other malignant neoplasms	24	18	22	18	23	26	20	24	21	26	17	22	24	25	27	26	21	19	21	21	21	20	23	23	25	17	21	25	24	25	22	24	
Falls	20	26	24	19	25	24	26	26	19	23	24	23	25	26	24	29	16	21	28	20	22	22	21	26	23	31	25	26	27	22	18	25	

Both sexes, Age-standardized, 2019, YLDs per 100,000



Higher rank Lower rank

	Alborz	Ardebil	Bushehr	Chaharmahal and Bakhtiari	E Azarbaijan	Fars	Gilan	Golestan	Hamadan	Hormozgan	Ilam	Iсфаهان	Kerman	Kermanshah	Khorasan	Khuzestan	Kohgiluyeh and Boyer-Ahmad	Kurdistan	Lorestan	Markazi	Mazandaran	N Khorasan	Qazvin	Qom	Semnan	Sistan and Baluchistan	S Khorasan	W Azarbaijan	Tehran	Yazd	Zanjan	Iran (Islamic Republic of)	
Low back pain	2	2	2	1	1	2	1	1	1	2	2	1	2	2	1	2	2	1	1	2	1	2	1	2	1	2	2	1	2	1	2	1	
Depressive disorders	1	1	1	2	3	1	2	4	2	1	1	2	1	1	3	1	1	2	4	1	2	1	2	1	2	1	1	2	1	2	1	2	
Headache disorders	3	3	3	3	2	3	3	2	3	3	3	3	3	3	4	4	3	3	2	3	3	4	3	3	3	3	4	3	3	5	3	3	
Anxiety disorders	4	4	4	4	4	4	4	3	4	4	4	4	4	4	5	5	4	4	3	4	4	5	4	4	4	4	5	4	4	3	4	4	
Diabetes	5	5	5	6	5	6	5	5	6	5	6	5	6	6	2	3	6	6	6	5	5	3	6	5	5	6	3	5	5	4	6	5	
Gynecological diseases	6	6	6	5	6	5	6	6	5	6	5	6	7	5	7	6	5	5	5	6	6	6	5	6	6	5	6	6	6	6	5	6	
Neck pain	8	7	7	8	7	7	7	7	7	7	7	7	8	7	8	7	7	7	7	7	7	7	7	7	7	7	8	7	7	7	7	7	
Age-related hearing loss	9	8	9	7	8	8	8	8	8	8	9	9	9	8	9	8	8	8	8	8	8	8	8	8	8	8	7	8	9	8	8	8	8
Other musculoskeletal	7	9	8	10	9	9	9	9	10	9	8	8	12	9	10	9	10	9	10	10	9	9	9	10	9	10	9	10	9	10	9	10	9
Blindness and vision loss	10	10	10	9	10	10	10	10	9	10	10	10	10	10	6	10	9	10	9	9	9	10	10	10	9	10	9	10	10	9	10	9	10
Oral disorders	11	11	11	11	11	11	12	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11	11
Endo/metab/blood/immune	12	12	12	12	12	12	13	12	13	13	12	12	14	13	12	12	12	12	12	12	12	12	12	12	12	12	13	12	13	12	12	12	12
Neonatal disorders	13	13	13	13	13	14	14	14	14	14	13	13	15	14	13	14	13	13	14	13	13	13	13	13	13	13	14	13	14	13	13	13	13
Drug use disorders	14	18	20	21	17	13	18	21	12	12	22	17	17	12	15	15	21	21	13	14	21	18	14	19	18	12	16	12	22	20	19	14	
Stroke	15	14	14	15	14	15	15	13	15	15	16	19	20	15	17	13	16	15	15	16	14	14	17	18	14	18	18	20	14	16	15	15	
Osteoarthritis	16	16	16	16	18	17	17	16	18	17	15	16	18	18	18	17	17	16	17	17	15	17	18	17	16	17	17	15	16	17	18	16	
Diarrheal diseases	17	15	15	14	16	16	16	15	16	16	14	14	16	17	16	16	15	14	16	15	16	15	15	16	15	16	15	18	15	15	16	17	
COPD	20	21	21	20	15	19	20	18	19	23	21	15	13	16	14	20	22	19	20	18	20	16	19	15	17	15	14	17	17	14	17	18	
Bipolar disorder	19	17	17	18	19	20	19	17	20	18	17	18	19	20	20	19	18	18	18	20	17	20	20	20	19	19	19	19	19	18	19	21	19
Falls	18	19	18	17	20	18	22	19	17	20	18	20	22	19	19	22	14	17	21	19	18	19	16	22	20	25	21	16	20	21	20	20	
Schizophrenia	21	20	19	19	21	21	21	20	21	19	19	21	21	21	21	21	19	20	19	21	19	21	21	21	21	20	20	21	19	22	22	21	
Asthma	23	23	24	22	22	25	23	22	24	24	24	22	25	24	22	26	25	25	23	24	23	22	22	24	23	21	22	22	21	24	23	22	
Chronic kidney disease	22	22	22	25	23	22	24	23	25	21	20	24	24	22	24	23	24	24	24	23	25	24	23	23	24	24	24	24	23	23	25	23	
Road injuries	26	25	23	23	24	23	25	24	23	22	23	23	23	23	23	24	23	23	25	25	22	23	24	31	25	23	23	35	24	25	24	24	
Alzheimer's disease	24	24	25	24	25	26	26	26	26	26	25	25	28	26	25	27	26	26	26	26	26	26	26	25	25	26	27	25	23	25	26	25	

روند احتمال مرگ 30 تا 70 ساله ، 1990 تا 2019

	National								Subnational							
2019	14.6%	13.7%	18.1%	16.2%	13.8%	16.2%	15.0%	16.5%	21.6%	16.4%	15.0%	17.2%	13.6%	15.4%	17.0%	16.6%
2018	14.7%	13.8%	18.3%	16.3%	14.0%	16.3%	15.1%	16.5%	21.7%	16.5%	15.2%	17.3%	13.6%	15.4%	17.1%	16.7%
2017	14.9%	14.1%	18.6%	16.7%	14.4%	16.4%	15.2%	16.6%	21.8%	16.8%	15.6%	17.5%	13.7%	15.4%	17.7%	17.1%
2016	15.0%	14.0%	19.0%	17.1%	15.2%	16.7%	15.4%	16.8%	21.8%	16.8%	15.9%	17.7%	13.8%	15.5%	17.6%	17.2%
2015	15.1%	13.9%	19.2%	17.6%	16.0%	17.0%	15.6%	17.0%	21.5%	16.8%	16.4%	18.1%	13.9%	15.7%	17.6%	17.3%
2014	15.1%	13.7%	18.9%	17.8%	16.2%	16.9%	15.7%	17.0%	21.0%	16.9%	16.7%	17.9%	13.6%	15.7%	17.5%	17.3%
2013	15.0%	13.6%	18.6%	18.1%	16.3%	16.6%	15.7%	17.0%	20.4%	17.1%	17.0%	17.9%	13.4%	15.8%	17.6%	17.5%
2012	15.0%	13.6%	18.3%	18.3%	16.3%	16.5%	15.5%	17.6%	19.9%	17.0%	17.2%	18.0%	13.1%	16.1%	17.7%	17.5%
2011	15.1%	13.8%	18.0%	18.6%	16.4%	16.5%	15.4%	18.0%	19.8%	17.0%	17.3%	18.1%	12.9%	16.5%	17.8%	17.1%
2010	15.4%	14.1%	17.9%	19.0%	16.7%	16.8%	15.7%	18.3%	20.1%	17.3%	17.6%	18.3%	13.1%	17.2%	18.4%	17.3%
2009	16.0%	14.5%	18.3%	19.5%	17.0%	17.3%	16.3%	19.3%	20.8%	17.7%	20.1%	18.5%	13.8%	17.7%	19.2%	18.1%
2008	16.4%	15.1%	18.4%	19.9%	17.3%	17.8%	16.6%	20.2%	21.2%	17.9%	20.3%	18.8%	14.2%	18.4%	19.7%	18.5%
2007	16.9%	15.9%	19.0%	20.3%	17.7%	18.4%	17.0%	20.6%	21.7%	18.1%	20.5%	20.3%	14.5%	19.2%	20.4%	19.2%
2006	17.6%	16.5%	19.4%	20.9%	18.2%	19.1%	17.8%	21.2%	22.5%	18.5%	21.0%	20.7%	15.2%	20.3%	21.6%	20.2%
2005	18.1%	16.9%	19.8%	21.2%	18.5%	19.5%	18.3%	21.6%	24.1%	18.4%	21.3%	20.8%	15.5%	21.1%	23.1%	21.0%
2004	18.5%	17.4%	20.2%	21.4%	18.9%	20.0%	18.8%	21.9%	24.5%	18.5%	21.7%	20.9%	15.9%	22.0%	23.8%	21.9%
2003	19.0%	17.9%	20.2%	21.6%	19.2%	20.5%	19.2%	22.1%	24.8%	18.7%	22.2%	21.1%	16.3%	22.5%	24.5%	22.8%
2002	19.4%	18.4%	20.3%	21.7%	19.5%	21.0%	19.5%	22.2%	25.0%	19.2%	22.5%	21.3%	16.6%	23.2%	25.1%	23.4%
2001	19.7%	18.8%	20.4%	21.8%	19.8%	21.4%	19.7%	22.4%	25.3%	19.6%	22.9%	21.4%	16.9%	23.7%	25.5%	23.5%
2000	20.0%	19.1%	20.6%	22.0%	20.0%	21.7%	20.0%	22.7%	25.5%	20.0%	23.2%	21.5%	17.1%	24.0%	25.9%	23.8%
1999	20.3%	19.4%	20.9%	22.2%	20.2%	21.9%	20.3%	23.0%	25.7%	20.3%	23.4%	21.7%	17.4%	24.3%	26.2%	24.2%
1998	20.6%	19.6%	21.2%	22.3%	20.5%	22.2%	20.7%	23.2%	25.8%	20.7%	23.7%	21.9%	17.6%	24.6%	26.6%	24.5%
1997	20.9%	19.8%	21.6%	22.5%	20.8%	22.4%	21.1%	23.5%	26.0%	21.1%	24.1%	22.2%	17.9%	24.9%	27.0%	24.9%
1996	21.1%	19.9%	22.1%	22.6%	21.1%	22.6%	21.4%	23.6%	26.2%	21.5%	24.3%	22.5%	18.0%	25.2%	27.4%	25.2%
1995	21.5%	20.2%	22.5%	23.1%	21.5%	22.9%	21.8%	23.9%	26.4%	22.0%	24.6%	22.9%	18.3%	25.5%	27.8%	25.8%
1994	21.8%	20.4%	23.2%	23.3%	21.8%	23.1%	22.2%	24.1%	26.5%	22.5%	24.8%	23.2%	18.6%	25.9%	28.3%	26.2%
1993	22.1%	20.6%	23.7%	23.4%	22.1%	23.4%	22.3%	24.3%	26.7%	23.0%	25.2%	23.6%	18.8%	26.1%	28.6%	26.7%
1992	22.5%	20.8%	24.3%	23.6%	22.5%	23.7%	23.0%	24.6%	26.9%	23.5%	25.7%	24.0%	19.0%	26.3%	29.0%	27.2%
1991	22.8%	20.8%	24.8%	23.8%	22.8%	24.2%	23.1%	24.8%	27.2%	24.0%	25.5%	24.1%	19.3%	26.6%	29.3%	27.6%
1990	23.2%	20.7%	25.3%	23.8%	23.1%	24.7%	23.6%	25.1%	27.5%	24.6%	25.9%	24.5%	19.6%	26.8%	29.6%	28.0%
	Iran	Alborz	Ardebil	Bushehr	Chahar Mahaal and Bakhtiari	East Azarbaijan	Fars	Gilan	Golestan	Hamadan	Hormozgan	Ilam	Isfahan	Kerman	Kermanshah	Khorasan-e-Razavi

روند احتمال مرگ 30 تا 70 ساله ، 1990 تا 2019

2019	18.3%	13.1%	15.8%	17.3%	13.6%	15.3%	17.4%	14.8%	13.4%	15.3%	18.3%	13.2%	9.1%	17.2%	13.7%	13.8%
2018	18.4%	13.2%	16.0%	17.5%	13.6%	15.4%	17.4%	15.0%	13.5%	15.5%	18.4%	13.3%	9.1%	17.2%	13.8%	14.0%
2017	18.5%	13.4%	16.2%	17.8%	13.9%	15.6%	17.6%	15.4%	13.5%	15.9%	18.5%	13.5%	9.1%	17.3%	13.9%	14.1%
2016	18.7%	13.5%	16.6%	18.1%	14.0%	15.6%	17.7%	15.9%	13.6%	16.4%	18.6%	13.5%	9.1%	17.4%	14.1%	14.2%
2015	18.8%	13.5%	17.1%	18.5%	13.9%	15.6%	17.8%	16.5%	13.7%	17.0%	18.9%	13.6%	9.2%	17.5%	14.2%	14.3%
2014	18.6%	13.2%	17.3%	18.6%	13.6%	15.5%	17.9%	16.5%	13.8%	17.2%	18.8%	13.6%	9.1%	17.3%	14.1%	14.5%
2013	18.5%	12.8%	17.5%	18.7%	13.6%	15.5%	17.9%	16.5%	14.2%	17.4%	18.7%	13.6%	9.1%	16.8%	14.1%	14.7%
2012	18.3%	12.5%	17.6%	18.7%	13.8%	15.8%	17.8%	16.5%	14.4%	17.5%	18.3%	13.7%	9.1%	16.4%	14.4%	15.1%
2011	18.4%	12.3%	17.8%	18.7%	14.1%	16.0%	17.6%	16.5%	15.0%	17.6%	18.1%	13.8%	9.1%	16.0%	14.6%	15.5%
2010	18.7%	12.5%	18.4%	19.0%	14.8%	16.3%	17.7%	16.8%	15.9%	18.0%	18.1%	14.3%	9.2%	16.1%	15.1%	16.1%
2009	19.4%	12.9%	18.9%	19.4%	15.5%	16.9%	18.2%	17.2%	17.1%	18.4%	18.3%	14.5%	9.5%	16.8%	15.7%	16.7%
2008	19.8%	13.1%	19.3%	19.8%	16.1%	17.3%	18.6%	17.4%	18.5%	18.7%	18.4%	14.7%	9.7%	17.3%	16.1%	17.3%
2007	20.2%	13.6%	19.8%	20.2%	16.8%	17.6%	19.2%	17.8%	19.5%	19.1%	18.7%	15.1%	10.0%	18.1%	16.7%	17.9%
2006	20.7%	14.4%	21.5%	20.8%	17.7%	17.9%	20.1%	18.3%	20.5%	19.6%	19.0%	15.6%	10.4%	19.4%	17.6%	18.7%
2005	21.3%	14.9%	21.5%	21.1%	18.2%	17.8%	20.6%	18.4%	21.1%	19.9%	19.1%	15.9%	10.7%	20.3%	18.4%	19.2%
2004	21.7%	15.4%	21.6%	21.6%	18.8%	17.9%	21.3%	18.6%	21.5%	20.3%	19.7%	16.2%	11.0%	21.2%	18.8%	19.5%
2003	22.1%	16.0%	21.9%	21.9%	19.4%	18.3%	21.9%	18.7%	21.7%	20.7%	20.3%	16.4%	11.3%	22.1%	19.1%	19.8%
2002	22.6%	16.5%	22.1%	22.2%	19.9%	18.6%	22.6%	18.7%	21.6%	21.0%	20.3%	16.7%	11.7%	22.7%	19.2%	19.8%
2001	23.0%	16.9%	22.4%	22.6%	20.2%	18.9%	23.1%	18.8%	21.7%	21.4%	20.6%	16.9%	12.0%	23.2%	19.5%	19.7%
2000	23.2%	17.3%	22.7%	23.0%	20.5%	19.0%	23.6%	19.0%	21.7%	21.6%	21.0%	17.3%	12.2%	23.6%	19.7%	19.6%
1999	23.5%	17.7%	23.1%	23.3%	20.9%	19.2%	24.0%	19.2%	21.9%	21.8%	21.2%	17.6%	12.5%	23.9%	20.0%	19.5%
1998	23.7%	18.1%	23.4%	23.5%	21.2%	19.3%	24.4%	19.4%	22.1%	22.0%	21.7%	18.0%	12.7%	24.3%	20.2%	19.5%
1997	23.8%	18.5%	23.7%	23.8%	21.6%	19.4%	24.8%	19.5%	22.3%	22.3%	22.0%	18.4%	13.0%	24.6%	20.4%	19.5%
1996	24.0%	18.8%	24.1%	24.1%	21.8%	19.5%	25.3%	19.6%	22.4%	22.4%	22.4%	18.9%	13.2%	24.9%	20.6%	19.6%
1995	24.1%	19.2%	24.6%	24.5%	22.2%	19.7%	25.8%	19.8%	22.6%	22.6%	22.8%	19.4%	13.4%	25.2%	20.8%	19.8%
1994	24.3%	19.7%	25.1%	24.8%	22.6%	19.9%	26.3%	19.9%	22.8%	22.9%	23.3%	20.0%	13.6%	25.6%	21.1%	19.9%
1993	24.5%	20.1%	25.7%	25.0%	23.0%	20.1%	26.8%	20.3%	23.1%	23.2%	23.6%	20.5%	13.8%	26.0%	21.1%	20.2%
1992	24.7%	20.4%	26.3%	25.4%	23.4%	20.3%	27.4%	20.6%	23.2%	23.1%	24.1%	21.1%	14.0%	26.3%	21.4%	20.4%
1991	25.0%	20.8%	26.8%	25.7%	23.7%	20.6%	27.8%	20.9%	23.0%	23.3%	24.5%	21.6%	14.2%	26.7%	21.5%	20.8%
1990	25.3%	21.2%	27.6%	26.1%	24.3%	21.0%	28.3%	21.3%	23.1%	23.4%	25.1%	22.0%	14.3%	27.2%	21.7%	21.3%

Khuzestan

Kohgiluyeh
and Boyer-Ahmad

Kurdistan

Lorestan

Markazi

Mazandaran

North Khorasan

Qazvin

Qom

Semnan

Sistan and
Baluchistan

South Khorasan

Tehran

West Azarbayejan

Yazd

Zanjan

of the
probability of
and


subnational levels,
1990-2019

Both sexes, Age-standardized, 2019, DALYs per 100,000



Higher rank Lower rank

	Alborz	Ardebil	Bushehr	Chaharmahal and Kohgiluyeh	E Azarbaijan	Fars	Gilan	Golestan	Hamadan	Hormozgan	Ilam	Isfahan	Kerman	Kermanshah	Khorasan	Khuzestan	Kohgiluyeh	Kurdistan	Lorestan	Mazandaran	Markazi	N Khorasan	Qazvin	Qom	Semnan	Sistan and Baluchistan	S Khorasan	Tehran	W Azarbaijan	Yazd	Zanjan	Iran (Islamic Republic of)		
High blood pressure	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	3	1	2	1	1
High body-mass index	3	2	3	2	2	2	2	2	2	2	2	3	2	2	3	3	2	2	2	2	2	2	2	3	2	2	3	2	3	2	3	3	2	2
High fasting plasma glucose	2	3	2	4	3	3	3	3	3	3	3	2	3	3	2	2	5	3	3	3	3	3	3	2	3	3	1	1	2	1	3	3	3	
Smoking	5	5	6	6	4	6	5	5	5	5	6	7	6	4	6	4	6	6	4	5	4	5	5	4	4	4	4	7	5	4	5	5	4	4
High LDL	4	4	5	3	5	5	4	4	4	4	4	5	6	4	6	5	3	5	4	5	4	4	5	5	5	5	5	6	6	4	6	5	5	
Particulate matter	6	6	4	5	7	4	6	6	6	6	5	5	4	5	5	5	4	4	6	6	6	6	6	6	6	6	6	4	4	5	6	4	6	6
Kidney dysfunction	7	7	7	8	6	7	7	7	7	7	7	6	7	8	7	7	7	7	8	7	7	7	7	7	7	7	7	6	8	8	7	8	8	7
Low birth weight & short gestation	9	8	8	9	9	8	9	9	8	8	8	8	7	8	8	9	9	7	10	8	9	8	9	9	8	8	8	7	7	8	7	7	8	
Low whole grains	8	9	9	7	8	9	8	8	9	9	9	9	9	9	9	8	8	9	8	9	8	9	8	8	9	9	9	9	9	10	9	9	9	9
Drug use	10	16	15	16	13	10	16	16	10	11	16	14	13	10	12	14	16	16	11	12	16	15	10	12	15	11	11	11	9	16	14	14	10	
Lead	16	10	10	10	10	11	11	10	11	10	10	15	10	11	11	10	10	10	9	11	14	10	11	10	12	10	10	19	10	12	10	11	11	
Low temperature	11	12	17	13	11	13	12	11	12	17	13	11	14	12	10	16	14	11	12	10	11	11	12	11	10	16	13	13	13	11	13	11	12	
Low physical activity	12	13	11	12	12	12	10	13	14	13	12	10	15	14	14	11	12	13	14	14	10	14	14	13	11	15	14	11	12	10	13	13	13	
Secondhand smoke	14	15	13	15	14	15	14	14	16	14	15	12	11	15	13	12	15	14	16	13	12	12	15	14	13	13	12	12	14	11	15	14	14	
Low legumes	13	11	12	11	15	14	13	12	13	12	11	13	12	13	15	13	11	12	13	15	13	13	13	15	14	12	15	14	13	15	12	15	15	
High trans fat	15	14	14	14	16	16	15	15	15	15	14	16	16	16	16	15	13	15	15	16	15	16	16	16	16	14	16	15	15	16	16	16	16	
Occupational ergonomic	20	17	24	19	22	20	18	21	20	21	18	20	18	20	19	24	19	17	17	18	17	17	20	23	20	27	17	17	17	19	17	17	17	
High red meat	17	18	18	21	18	19	17	17	19	19	19	17	24	18	20	18	18	21	18	21	18	20	19	18	18	23	23	20	20	17	20	18	18	
Alcohol use	18	21	20	24	17	17	19	18	17	18	21	19	17	17	18	19	22	20	20	19	20	19	18	19	19	19	18	19	21	21	20	21	19	
Low bone mineral density	21	24	19	18	19	18	22	22	18	20	20	18	20	19	17	26	17	18	19	17	19	18	17	21	17	22	18	22	22	18	18	18	20	
Occupational injury	22	20	22	17	21	23	23	25	23	23	24	21	25	23	21	23	20	19	23	20	23	23	21	17	21	21	20	16	19	21	19	21		
Intimate partner violence	19	23	21	28	25	21	25	28	27	26	17	22	22	21	26	21	21	24	29	22	21	24	25	20	26	26	24	18	18	25	23	22		
Unsafe water	25	25	26	20	23	25	24	26	24	22	25	23	23	25	22	27	25	23	25	23	26	22	23	22	23	19	21	24	24	22	22	23		
High sodium	24	19	23	22	20	22	20	20	22	24	22	26	28	22	23	22	24	22	21	24	22	21	22	25	22	25	26	28	23	23	24	24		
Low omega-3	23	22	25	23	24	24	21	19	21	25	23	25	27	24	25	20	23	25	22	27	24	26	24	26	24	29	30	30	25	29	25	25		



بالتسکر